Page 33 - JCTR-9-6
P. 33

Lubimova et al. | Journal of Clinical and Translational Research 2023; 9(6): 392-397   397
             Avčin  T,  Toplak  N.  Vaccination  Coverage  in  Children   Immunosuppressed Patients with Inflammatory Rheumatic
             with Rheumatic Diseases. Clin Exp Rheumatol 2020;38:     Diseases  and  Healthy  Controls.  Vaccine  2022;40:
             164-70.                                                  4897-904.
        [24]  Morin MP, Quach C, Fortin E, Chédeville G. Vaccination   [34]  Nerome Y, Akaike H, Nonaka Y, Takezaki T, Kubota T,
             Coverage  in  Children  with  Juvenile  Idiopathic       Yamato  T,  et al.  The  Safety  and  Effectiveness  of  HBV
             Arthritis  Followed  at  a  Paediatric  Tertiary  Care  Centre.   Vaccination in Patients with Juvenile Idiopathic Arthritis
             Rheumatology (Oxford) 2012;51:2046-50.                   Controlled  by  Treatment.  Mod  Rheumatol  2016;26:
        [25]  Minden  K,  Niewerth  M,  Borte  M,  Singendonk  W,     368-71.
             Haas  JP.  Impfungen  bei  Rheumatischen  Erkrankungen   [35]  Heijstek MW, Kamphuis S, Armbrust W, Swart J, Gorter S,
             des  Kindes-und  Jugendalters  [Immunization  in  Children   de Vries LD, et al. Effects of the Live Attenuated Measles-
             and Adolescents with Rheumatic Diseases]. Z Rheumatol    Mumps-Rubella Booster Vaccination on Disease Activity in
             2007;66:111-2, 114-8, 120.                               Patients with Juvenile Idiopathic Arthritis: A Randomized
        [26]  Crawford  NW,  Buttery  JP.  Adverse  Events  Following   Trial. JAMA 2013;309:2449-56.
             Immunizations:  Fact  and  Fiction.  Paediatr  Child  Health   [36]  Uziel  Y,  Moshe  V,  Onozo  B,  Kulcsár  A,  Tróbert-
             2013;23:121-4.                                           Sipos  D,  Akikusa  JD,  et al.  Live  Attenuated  MMR/V
        [27]  Silva CA, Terreri MT, Aikawa NE, Carvalho JF, Pileggi GC,   Booster  Vaccines  in  Children  with  Rheumatic  Diseases
             Ferriani VP, et al. Vaccination Practice in Children with   on  Immunosuppressive  Therapy  are  Safe:  Multicenter,
             Rheumatic Disease. Rev Bras Reumatol 2010;50:351-61.     Retrospective Data Collection. Vaccine 2020;38:2198-201.
        [28]  Vazhappilly S, Vanderkooi O, Benseler S, Gerschman T,   [37]  Hamad Saied M, van Straalen JW, de Roock S, de Joode-
             Johnson N, Luca N, et al. Immunization Status and Barriers   Smink  GC,  Swart  JF,  Wulffraat  NM,  et  al.  Safety  of
             in  Childhood  Rheumatic  Diseases  (Abstract).  American   Measles-Mumps-Rubella Booster Vaccination in Patients
             College  of  Rheumatology/Association  of  Rheumatology   with Juvenile Idiopathic Arthritis: A Long-Term Follow-up
             Health Professionals Annual Meeting; 2014.               Study. Vaccine 2023;41:2976-81.
        [29]  Riaz  A,  Husain  S,  Yousafzai  MT,  Nisar  I,  Shaheen  F,   [38]  Alfayadh  NM,  Gowdie  PJ,  Akikusa  JD,  Easton  ML,
             Mahesar  W,  et al.  Reasons  for  Non-Vaccination  and   Buttery JP. Vaccinations Do Not Increase Arthritis Flares in
             Incomplete  Vaccinations  Among  Children  in  Pakistan.   Juvenile Idiopathic Arthritis: A Study of the Relationship
             Vaccine 2018;36:5288-93.                                 between Routine Childhood Vaccinations on the Australian
        [30]  Brunner HI, Tzaribachev N, Cornejo GV, Joos R, Gervais E,   Immunisation Schedule and Arthritis Activity in Children
             Cimaz  R,  et al.  Maintenance  of  Antibody  Response  to   with Juvenile  Idiopathic  Arthritis. Int J Rheumatol
             Diphtheria/Tetanus  Vaccine  in  Patients  Aged  2-5 Years   2020;2020:1078914.
             with  Polyarticular-Course  Juvenile  Idiopathic  Arthritis   [39]  Toplak N, Uziel Y. Vaccination for Children on Biologics.
             Receiving  Subcutaneous  Abatacept.  Pediatr  Rheumatol   Curr Rheumatol Rep 2020;22:26.
             Online J 2020;18:19.                               [40]  Kostik  MM,  Lubimova  NA,  Fridman  IV,  Goleva  OV,
        [31]  Heijstek  MW,  van  Gageldonk  PG,  Berbers  GA,        Kharit SM. The Vaccine Coverage and Vaccine Immunity
             Wulffraat  NM.  Differences  in  Persistence  of  Measles,   Status  and  Risk  Factors  of  Non-Protective  Levels  of
             Mumps,  Rubella,  Diphtheria  and  Tetanus  Antibodies   Antibodies  Against  Vaccines  in  Children  with  Juvenile
             between  Children  with  Rheumatic  Disease  and  Healthy   Idiopathic  Arthritis:  Cross-Sectional  Russian  Tertiary
             Controls:  A  Retrospective  Cross-Sectional  Study.  Ann   Centre Study. Pediatr Rheumatol Online J 2021;19:108.
             Rheum Dis 2012;71:948-54.                          [41]  Bednarek A, Klepacz R. Vaccinology Education of Nurses
        [32]  Bühler S, Jaeger VK, Adler S, Bannert B, Brümmerhoff C,   and  the  Current  Immunoprophylaxis  Recommendations
             Ciurea A,  et al.  Safety  and  Immunogenicity  of Tetanus/  for Children with Juvenile Idiopathic Arthritis. J Clin Med
             Diphtheria  Vaccination  in  Patients  with  Rheumatic   2020;9:3736.
             Diseases-A  Prospective  Multi-Centre  Cohort  Study.   [42]  Davies K, Woo P, British Paediatric Rheumatology Group.
             Rheumatology (Oxford) 2019;58:1585-96.                   Immunization  in  Rheumatic  Diseases  of  Childhood:
        [33]  Mischlinger  J,  Jaeger  VK,  Ciurea  A,  Gabay  C,     An  Audit  of  the  Clinical  Practice  of  British  Paediatric
             Hasler  P,  Mueller  RB,  et  al.  Long-Term  Persistence  of   Rheumatology  Group  Members  and  a  Review  of  the
             Antibodies  After  Diphtheria/Tetanus  Vaccination  in   Evidence. Rheumatology (Oxford) 2002;41:937-41.




                                                                Publisher’s note
                                                                AccScience Publishing remains neutral with regard to jurisdictional
                                                                claims in published maps and institutional affiliations.
                                          DOI: http://dx.doi.org/10.18053/jctres.09.202306.23-00103
   28   29   30   31   32   33   34   35   36   37   38